

Research on analytical methods of analysis of Ranolazine: A Review

Available online at www.hjhs.co.in

REVIEW ARTICLE

Priyanka Patil *, Shyam Rangari, Priya Patil

Department of Quality Assurance Technique, KYDSCT's College of Pharmacy, Sakegaon, Bhusawal, Jalgaon-425 201, Maharashtra, India.

DOI [10.22270/hjhs.v5i4.79](https://doi.org/10.22270/hjhs.v5i4.79)

ABSTRACT

New antianginal drugs examines are focusing on promising concentrations in order to develop new prescription contenders. Fundamental and biochemical strategy feeble connection between seriousness of torment and level of oxygen hardship in the heart muscle, for instance at times, angina can be very extreme, and in the mid twentieth century this was a known indication of looming demise, can accept an essential activity in the distinctive evidence of these goals. Compounding angina assaults, abrupt beginning angina very still, and angina enduring over 15 minutes are indications of flimsy angina (normally gathered with comparative conditions as the intense coronary disorder). As these may go before a respiratory failure, they require critical clinical consideration and are, all in all, rewarded in comparative design to myocardial localized necrosis. The pharmaceutical undertakings are centered around new drug improvement due to the overall affirmation of this unsafe security from the correct now available antianginal treatment. The HPLC, UV and HPTLC methods are available for the assessment of Ranolazine the starting late used prescription for intestinal sickness are studied in this articles.

Keywords: Antianginal Drugs, Ranolazine, analysis

1. Introduction

Angina pectoris is a clinical indication that outcomes from coronary atherosclerotic coronary illness. An intense anginal assault (optional angina) is thought to happen in view of unevenness between myocardial oxygen flexibly and request attributable to the powerlessness of coronary blood stream to increment with respect to increments in myocardial oxygen prerequisites. This is commonly the aftereffect of extreme coronary vein atherosclerosis. Angina pectoris (variation, essential angina) may likewise happen because of vasospasm of enormous epicardial coronary vessels or one of their significant branches. Furthermore, angina in specific patients may result from a blend of coronary vasoconstriction, platelet collection, plaque break, and an expansion in myocardial oxygen request (crescendo or flimsy angina). According to the World Cardiovascular maladies Report (2019), an expected 17.9 million individuals passed on from cardiovascular illnesses in 2016, speaking to 31% of every worldwide demise. Of these passing, 85% are because of coronary failure and stroke. (1-4)

Antianginal Drugs (3-7)

Antianginal medications may soothe assaults of intense myocardial ischemia by expanding myocardial oxygen gracefully or by diminishing myocardial oxygen request or both. Three gatherings of pharmacological specialists have been demonstrated to be powerful in lessening the recurrence, seriousness, or both of essential or optional angina. These specialists incorporate the nitrates, β -adrenoceptor enemies. What's more, calcium section blockers. To comprehend the gainful activities of these specialists, it is essential to be acquainted with the central point managing the harmony between myocardial oxygen gracefully and request.

The Classes are:

Vasodilators compounds (VC)

The contractile movement of a wide range of muscle is controlled essentially by the reversible phosphorylation of myosin. Along with actin they take an interest in a course of biochemical occasions that are a piece of the procedures of muscle compression and unwinding. Nitrates shows vasodilating impact, which brings about decrease of fringe

obstruction during myocardial constrictions. The vasodilator meds under this class joins nitrates, calcium blocker, for example, Isosorbide dinitrate, Pentaerythritol tetranitrate, Isosorbide mononitrate and Nitroglycerin, and so on.

Cardiac depressants compounds (CDC)

Cardiac depressants compounds (CDC) like calcium blocker, and beta-blocker, for instance, verapamil, calcium particles assume a significant job in the guideline of numerous cell forms, for example, synaptic transmission and muscle constriction. Calcium channel blockers lessen or forestall the expansion of free cytosolic calcium particles by meddling with the vehicle of calcium particles through these pores. Ex. Atenolol, Propranolol, Metoprolol, Diltiazem and Verapamil, and so on.

Miscellaneous compounds (MC)

Miscellaneous compounds (MC) acts non-aerodynamically, forestalls corruption of layer unsaturated fats by lipid peroxidation decreases myocardial O₂ request - pFOX inhibitor and furthermore represses superoxide cytotoxicity - shields myocin from unsafe impacts of ischemia. What's more, it squares late internal sodium flows in cardiomyocytes. In the ischemic myocardium, late internal sodium flows add to a rise in intracellular sodium, which prompts an expansion in intracellular calcium through the sodium-calcium exchanger. Calcium over-burden in ischemic cells prompts hindered unwinding, cardio protective additionally restrains unsaturated fat oxidation. The various compounds under this characterization consolidates Ivabradine, Ranolazine and Trimetazidine, and so on.

Angina pectoris is the consequence of myocardial ischemia brought about by unevenness between myocardial blood gracefully and oxygen request. It is a typical introducing side effect (commonly, chest torment) among patients with coronary artery disease (CAD). Roughly 9.8 million Americans are assessed to encounter angina yearly, with 500,000 new instances of angina happening each year. Individuals with a normal age of 62 years, who have moderate to

extreme degrees of angina (reviewing by classes II, III, and IV) have a 5-year endurance pace of around 92%. (1) This overview moreover analyzes present day and front line distinctive consistent approaches to manage antianginal cure like ranolazine, methodology improvement with UV, HPLC, HPTLC, GC-MS and LC-MS including the various methodologies.

Ranolazine (ROZ) (8-10)

Ranolazine (ROZ) is hinders persevering or late internal sodium current in heart muscle in an assortment of voltage-gated sodium channels. Repressing that present prompts decreases in intracellular calcium levels. This thus prompts diminished pressure in the heart divider, prompting decreased oxygen necessities for the muscle. Ranolazine likewise shows its consequences for the postponed rectifier current, it promptly invigorates myogenesis, it diminishes a genius oxidant irritation/oxidative condition, and actuates the calcium flagging pathway. The chemical name of ranolazine is N-(2, 6-dimethylphenyl) -2-{4-[2-hydroxy -3-(2-methoxyphenoxy) propyl] piperazin-1-yl} acetamide. The atomic equation of ROZ is C₁₂H₃₃N₃O₄ and sub-atomic load of ROZ is 427.537 g/mol.

It has the following structural formula,




Figure 1. Structural formula of Ranolazine

Ranolazine is white to off-white solid with dissolvability in natural solvents, for example, dichloromethane and methanol, sparingly soluble in tetrahydrofuran, ethanol, acetonitrile, and acetone, slightly soluble in ethyl acetate, iso-propanol, toluene, and ethyl ether; and very slightly soluble in water. The partition coefficient (log p) for ROZ is 2.07 and Pka is 2.2.

Ranolazine is a piperazine subordinate is another enemy of ischemic medication for the treatment of angina. Ranolazine is to restrain

late INA accordingly forestalling sodium overburden of the cell. As an outcome, ranolazine forestalls switch mode sodium–calcium trade and hence diastolic amassing of calcium perhaps bringing about improved diastolic tone and improved coronary blood stream. This audit article speaks to the different expository strategies which has been accounted for estimation of Ranolazine in manufactured blend. (2-4, 6,10)

2. HPLC Method of Analysis of Antianginal Drugs

High Performance Liquid Chromatography (HPLC) is a separation system, it disconnects mix containing in any event two sections under high

pressure. In HPLC Stationary stage is full in one completion of fragment which is attached to a wellspring of pressurized liquid versatile stage. HPLC is a speediest creating logical method for the examination of the prescription. Its ease, high distinction and wide extent of affectability makes it ideal for the examination of various drugs in the two estimations structure and regular fluids. A couple HPLC procedures were represented the examination of antianginal cure in the mass, portion structure and characteristic fluids. (11-13)




Figure 2. HPLC Method of Analysis of Antianginal Drugs

A summary of research take a shot at a few expository techniques (HPLC, UV, HPTLC, UPLC and MS) announced for

the ranolazine alone and in blend is give in Table 1.

Table 1. A summary of research work on the analytical methods for the estimation of ranolazine alone and in the combination

Sr. No.	Drug	Method	Instrument, Mobile Phase, RT, Flow Rate & Results of Validation
1.	Ranolazine	UV-Method	M.Phase :- Methanol λ _{max} :- 272 nm Results :- R ² -0.999, Slope and intercept- 0.0061 and - 0.0118 Detection Limit (µg/mL)- 0.27 Quantification limit (µg/mL)- 0.82 .(14)
2.	Ranolazine	UV-Method	M.Phase :- 0.2% v/v ortho phosphoric acid λ _{max} :- 271 nm Results :- R ² -0.999, Slope and intercept- 0.006 and 0.0048 LOD - 0.807 µg/ml

			LOQ - 2.4460 µg/ml (15)
3.	Ranolazine	UV-Method	M.Phase :- Methanol and distilled water λ _{max} :- 263 nm & 282 nm. Result- R ² -0.9992, LOD - 0.0072 LOQ - 0.021 (16)
4.	Ranolazine	UV-Method	M.Phase :- Water λ _{max} :- 447 nm, Result- R ² -0.9997, Slope and intercept- 0.0482 and 0.0171 % RSD – 1.140 % Recovery- 99.99 (17)
5.	Ranolazine	UV-Method	M.Phase :- Synthetic mixture λ _{max} :- 272 nm. Result :- R ² -0.9995, Slope and intercept- 0.0005 and 0.0104 % RSD :- less than 2 , % Recovery:- 92.18-96.17 (18)
6.	Amiodarone Hydrochloride and Ranolazine	UV-Method	M.Phase :- synthetic mixture λ _{max} :- 263 nm & 249 nm. Result :- R ² -0.9996 for ADH & 0.9996 for ROZ LOD :- 0.712 µg/ml and 0.823 µg/ml LOQ:- 0.235 µg/ml and 0.271 µg/ml (19)
7.	Ranolazine	UV-Method & HPLC.	M.Phase :- 0.05M HCl λ _{max} :- 272 nm. Result :- Slope and intercept- 0.00587 and 0.00093 R ² -0.9993, LOD :- 0.25 µg/ml , LOQ:- 1.00 µg/ml. HPLC: M.Phase :- Acetonitrile: 20 mM Ammonium acetate buffer (55 : 45, v / v) Flow Rate :- 1.0 ml/min at 270 nm Result:- R. Time :- 3.8 min., R ² -0.9995 . LOD :- 0.5 ng/ml LOQ :- 0.5 ng/ml (20)
8.	Ranolazine and Dronedarone	LC-UV	M.Phase :- Acetonitrile: 0.02N NH ₂ PO ₄ buffer (50:50, v / v) Flow Rate :- 1.0 ml/min at 282 nm Result:- R. Time :- 0.25 & 0.16 min., R ² -0.9999. LOD :- 0.39 and 0.58 ng/ml

			LOQ :- 1.19 and 1.76 ng/ml (21)
9.	Ranolazine	LC-UV	M.Phase :- Acetonitrile – Sodium di-hydrogen phosphate monohydrate buffer (40:60 v/v) Flow Rate :- 1.0 ml/min at 225 nm Result:- R. Time :- 4.0 min., R^2 -0.9999. LOD :- 1.03 ng/ml LOQ :- 0.34 ng/ml (22)
10.	Ranolazine	HPLC.	M.Phase :- Methanol-acetonitrile-phosphate buffer (pH 3.6; 6.3 mM) (4:3:3, v/v/v) Flow Rate :- 1 ml/min at 254 nm Result:- R. Time :- 1.82 min., R^2 -0.9999. LOD :- 0.04 µg/ml , LOQ:- 0.12 µg/ml. (23)
11.	Ranolazine	HPLC.	M.Phase :- Methanol- phosphate buffer (pH-7) (65:35 v/v) Flow Rate :- 1 ml/min at 220 nm Result:- R. Time :- 10.49 min., R^2 - 0.9999. LOD :- 0.0273 µg/ml LOQ:- 0.0818 µg/ml (24)
12.	Ranolazine	HPLC.	M.Phase :- Buffer- acetonitrile (90:10 v/v) and Acetonitrile-water (90:10 v/v) Flow Rate :- 1 ml/min Result:- R. Time :- 11.94 min., R^2 -0.999. LOD :- 1000 µg/ml LOQ:- 1000 µg/ml (25)
13.	Ranolazine enantiomers	LC-UV.	M.Phase :- Methanol Flow Rate :- 1.0 ml/min λ_{max} :- 254 nm. Result:- R. Time :- 4.7 & 6.4 min., R^2 -0.997 & 0.999. LOQ:- 0.8 & 1.1 µg/mL (26)
14.	Ranolazine	RP-HPLC.	M.Phase :- Potassium dihydrogen phosphate monohydrate: methanol: acetonitrile (40:40:20) v/v Flow Rate: - 1.2 ml/min at 225 nm. Result:- R. Time :- 4 min., R^2 -0.9998. LOD:- 0.34 µg/mL LOQ: - 1.03 µg/mL. (27)

15.	Ranolazine	HPLC in dog plasma sample.	M.Phase :- Acetonitrile-water(7 mmol·L ⁻¹ ammonium acetate,3.5 mmol·L ⁻¹ acetic acid and 1‰ triethylamine) (50:50) Flow Rate: - 0.8 ml/min at 230 nm. Result:- R. Time :- min., R ² - 0.9998 % Recovery: - 88%-105%.(28)
16.	Ranolazine	RP-HPLC.	M.Phase :- Sodium di-hydrogen phosphate buffer : Acetonitrile (60:40) v/v) Flow Rate :- 1.0 ml/min Result:- R. Time :- 4 min., R ² - 0.9998 LOD:- 0.34 µg/mL LOQ: - 1.03 µg/ml. (29)
17.	Ranolazine	HPLC in Synthetic sample.	M.Phase :- hexane : 2-propanol (90 : 10) Flow Rate :- 1 ml/min Result:- R ² - >0.988 % RSD :- less than 2 , % Recovery:- 92.18-96.17 (30)
18.	Ranolazine	LLE-HPLC in human plasma	M.Phase :- Acetonitrile: phosphate buffer (pH 2, 20 mM) (40:60 v/v) λ _{max} :- 225nm Results :- R. Time :- 3.73 min., R ² -0.998. LOQ: 80 µg/ml, (31)
19.	Ranolazine	RP-UPLC Method	M.Phase :- Acetonitrile-Sodium dihydrogenphosphate (pH7.3;0.01 M)-Triethylamine (10:90:0.1,v/v/v) λ _{max} :- 223 nm Results :- R ² -0.9975, R. Time :- 10.25 Detection Limit – 0.006 Quatification limit – 0.15 (32)
20.	Ranolazine	HPLC-FD, HPLC-UV, LC-MS/MS in clinical pharmacokinetics	HPLC-FD M.Phase :- Methanol-Potassium phosphate monobasic 0.01 mol/L - Acetonitrile (45 : 40 : 15, v/v/v) Flow rate; - 1 ml/min. λ _{max} :- 229 nm HPLC M.Phase:- N-heptane/2-propanol/alcohol [ethanol]/diethylamine (60 : 15 : 25 : 0.2, v/v/v/v) Flow rate ;- 1 ml/min. λ _{max} :- 229 nm LC-MS/MS M.Phase :- Water containing 0.1% formic acid & Acetonitrile containing 0.1% formic acid

			Flow rate :- 1 ml/min. λ_{\max} :- 223 nm (33)
21.	Ranolazine	LC- MS/MS in plasma	M.Phase :- 0.125 % v/v trifluoroacetic acid in water adjusted to pH 3 with ammonia Flow Rate: - 1. ml/min. HPLC :- R. Time: - 27.41 min. R^2 0.998, Recovery:- 85%, (34)
22.	Ranolazine	LC-MS/MS in dog plasma	M.Phase:- Acetonitrile 0.05% acetic acid (60:40, v/v) Flow Rate: - 2 ml/min. HPLC :- R^2 0.999, Recovery:- 80-91%, Absolute bioavailability -72.6% Peak concentration – 4.32 $\mu\text{g/mL}$ (35)
23.	Ranolazine	LC-MS/MS in human plasma	M.Phase :- Acetonitrile-0.1% formic acid (90:10). Flow Rate :- 1.0 ml/min. HPLC :- R. Time :- 6 min R^2 0.9998 Recovery:- 75% LOQ:- 20 ng/ml (36)
24.	Ranolazine	HPLC- MS in human plasma	M.Phase :- Methanol–10mM Ammonium acetate (60:40 v/v) Flow Rate :- 1.0 ml/min. HPLC :- R. Time :- 1.93 min LOD :- 1 ng/mL LOQ:- 10 ng/mL (37)
25.	Ranolazine	LC- EI-MS in Rat plasma	M.Phase :- Methanol–10 mM Ammonium acetate, (76:24 v/v). Flow Rate :- 1.0 ml/min HPLC :- R. Time :- 4.2 min Recovery :- 82.77–86.54%. LOQ:- 46 ng/mL (38)
26.	Ranolazine	LC–MS– MS in human plasma	M.Phase :- Acetonitrile–Water–Formic acid– 10% N- butylamine (70:30:0.5:0.08, v/v/v/v) Flow Rate :- 5 $\mu\text{l/min}$ HPLC :- R. Time :- 1.12 min R^2 0.995. LOQ:- 5 $\mu\text{g/ml}$ (39)
27.	Ranolazine	LC-MS/Ms in human plasma	M.Phase :- :- Methanol–Water containing formic acid (1.0%, v/v) (65:35, v/v) Flow Rate :- 1.0 ml/min Result:- R. Time :- 4.38 min., R^2 0.9937. LOQ:- 5.0 ng/ml (40)

28.	Ranolazine and its three metabolites	LC-MS/Ms in human plasma.	M.Phase :- 5 mM Ammonium acetate aq.- Methanol. Flow Rate :- 0.5 ml/min Result:- R. Time :- 4.04 min., R^2 -0.9998. Recovery:- 84.2 -108% LOQ:- 4 ng/ml (41)
29.	Ranolazine and its metabolites desmethyl ranolazine	DLLME and LC-MS/MS	M.Phase :- :- Hexane:Ethanol (60/40, v/v) Flow Rate :- 10 μ l /min Result:- R. Time :- 5.66 & 13.54 min for ROZ 3.36 & 4.10 min. for DROZ R^2 -0.9873 & 0.9891 for ROZ 0.9953 & 0.9944 for DROZ LOQ:- 25 and 10 ng/ml (42)
30.	Ranolazine	LC-APCI-MS in human plasma.	M.Phase :- Aqueous ammonium acetate (20 mM) and trifluoroacetic acid (TFA, 0.12%) : methanolic ammonium acetate (20 mM) and TFA (0.12%) (40: 60 v/v) Flow Rate :- 1 ml/min Result:- R. Time :- 2.38 min., R^2 -0.996. Inter-assay variation:- 18.5% (43)
31.	Ranolazine	LC-APCI-MS in dog plasma.	M.Phase :- :- Acetonitrile-0.05% formic acid (60:40v/v) Flow Rate :- 0.3 ml/min Result:- R. Time :- 3.8 min. R^2 -0.998. LOD:- 0.002 mg/mL LOQ:- 0.01 mg/mL (44)
32.	Ranolazine	U-HPLC-MS/MS in human plasma.	M.Phase Acetonitrile - Aqueous ammonium acetate solution (40:60, v/v). Flow Rate :- 0.35 ml/min Result:- R. Time :- 1.01 min., R^2 - \geq 0.997. Recovery:- 85 – 100.4% LOQ:- 1.0 ng/ml (45)
33.	Ranolazine	DRIFTS-Method	M.Phase :- Potassium bromide Detection :- 4000 and 650 cm^{-1} Std. Peak:- Carbonyl peak around 1689 cm. Result:- Resolution :- 8, R^2 -0.9987. RSD:- 0.957-1.001 Recovery:- 95.58–97.12% (46)

34.	Ranolazine	HPTLC Method	M.Phase :- Chloroform : Methanol : Toluene (5 : 1 : 1 v/v/v) λ _{max} :- 273nm Results :- R _f value:- 0.15 to 0.79 R ² 0.9999, LOD:- 250 ng/spot LOQ;- 440 ng/spot (47)
35.	Ranolazine	HPTLC-MS	M.Phase :- Butanol–Acetic acid–water (6:2:2 v/v) λ _{max} :- 270 nm Results :- R _f value:- 0.56 R ² 0.9999, LOD:- 14.9 ng/band LOQ;- 49.67 ng/band (48)
36.	Ranolazine	Headspace GC	S.Phase :- DB-624 capillary column (30m×0.32mm×1.8μm) Detector :- FID % RSD :- 1.1-3.7% Recovery:- 98.1%-105.5% (49)
37.	Ranolazine	Headspace GC	S.Phase:- HP-INNOWAX column Solvent :- Water Detector :- FID % RSD of precision and accuracy:- less than 8% Recovery:- 87.1%-105.6%. (50)

3. Conclusion

In spite of the way that couple of indicative procedures (HPLC, UV, HPTLC, UPLC and MS) are represented there is a continued with necessity for developing continuously beneficial, sensitive, precise and accurate systems for the assessment of the ranolazine alone and in blend in the portion structures and in the natural fluids. The introduced data is valuable for the future examination for analyst associated with definition improvement and quality control of Ranolazine

Acknowledgements

I would like to express my gratitude to Himalayan Journal of Health Sciences who gave me the opportunity to publish the article.

Financial Disclosure statement: The author received no specific funding for this work.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

References

- 1) World Malarial Report-2019, Geneva: World Health Organization (WHO); 2019.p.1-232.
- 2) Patel Vishakha. D.,Raj. Hasumati. Ranolazine: A Review on Analytical Method and Its Determination in Synthetic Mixture. International Journal of Pharmaceutical Research & Allied Sciences. 2016;5(1):1-7.
- 3) Craig I Coleman, Nick Freemantle, Christine G Kohn, Ranolazine For The Treatment Of Chronic Stable Angina: A Cost-Effectiveness Analysis From The UK Perspective. BMJ Open. 2015;5(11):1-8.
- 4) Patel Vishakha. D., Raj Hasumati. A Review on Analytical Method and Its Determination in Synthetic Mixture. Asian J. Pharm. Ana. 2015; 5(4):214-218.
- 5) Georgia Kourlaba, Charalambos Vlachopoulos, John Parissis, John Kanakakis,et.al.. Ranolazine For The Symptomatic Treatment Of Patients With Chronic Angina Pectoris In Greece: A Cost-Utility Study. BMC Health Services Research. 2015;15:566.
- 6) Khalid Khan, Matthew Jones. Ranolazine In The Management Of Chronic Stable Angina. Br J Cardiol. (2011);18:179.
- 7) Chidananda Swamy Rumalla, Kishore Babu Bonige, Jagadeesh Narkedimilli, Raghu Babu Korupolu,et.al. Isolation And Structural Elucidation Of Degradation Products Of Ranolazine. International Journal of Pharmaceutical Sciences and Research. 2019;10(8):3763-3769.
- 8) Wikipedia- Ranolazine [Internet]. Wikipedia; 2020 [cited 2020 Sept.15]. Available from: www.wikipeda.com

8. Jules C Hancox, Sheila A Doggrell, Persceptive: Does ranolazine have potential for the treatment of atrial fibrillation? Expert Opinion on Investigational Drugs [Internet]. drugbank; 2010 [cited 2020 Sept.15]. Available from: www.drugbank.ca.
9. 10David Harvey, Modern Analytical Chemistry. The McGraw-Hill Companies, 1st edition; 1996.
10. D. Skoog, et al. Principles of Instrumental Analysis, 2nd edition. Congress Cataloging publication; 1980.
11. Lloyd R. Snyder, Joseph J. Kirkland, John W. Dolan. 3rd edition Introduction to Modern Liquid Chromatography. A John Wiley & Sons, Inc. Publication; 2010.
12. Ashish Sharma, Dev Prakash, Sachin Kumar Singh. Development and Validation of UV Spectrophotometric Method for the Estimation of Ranolazine in Bulk Drug and Pharmaceutical Formulation, International Journal of ChemTech Research. 2010; 2(4): 1945-1948.
13. DVS Roopa Sirisha Doppa, Sathish Kumar Konidala, Sheik Khanabhi, Development and Validation of UV Spectroscopic Method for the Determination of Ranolazine in Bulk and Formulation, Research Journal of Pharmacy and Technology, 2019;12(10): 5007-5010.
14. J. Ramesh, Rajasekhar K, Kiran Gandhi R and Senthil Kumar N. Method Development And Validation For The Estimation Of Ranolazine In Bulk And In Pharmaceutical Dosage Form By UV-Spectrophotometry. Annals of Pharma Research; 2013;01 (1):4-7.
15. Naveen Kumar GS, Harish KH, Dinesh M and Hanumanthachar Joshi. Spectrophotometric Method For The Estimation Of Ranolazine In Bulk And Pharmaceutical Formulations. Unique Research Journal of Chemistry. 2014; 02(01):5-7.
16. Vishakha D. Patel, Hasumati A. Raj, Nirav K. Gheewala. Second Derivative Spectroscopic Method for Simultaneous estimation of Amiodarone Hydrochloride and Ranolazine in synthetic mixture. Asian Journal of Pharmaceutical Analysis. 2016;6(1):23-30.
- 19) Rakesh Kumar Singh, Pankaj Singh Pate , Paras Malik and Tej Pratap Singh Nanodrop. Spectrophotometric Method Development and Validation for Estimation of Ranolazine in Their Bulk. International Journal of Pharmaceutical Sciences and Research. 2014; 2(4):985-998.
- 20) C. Nishith, et al.. Development and validation of analytical methods for quantitative estimation of ranolazine. (/jspui/handle/123456789/194).
- 21) Asifa Nahid, Haritha Pavani, Development and validation of HPLC method for simultaneous determination of Ranolazine and Dronedaronone in bulk and pharmaceutical dosage forms. Indian Journal of Research in Pharmacy and Biotechnology. 2014;2(6):1524-1528.
- 22) Ganji Ramanaiah , D. Ramachandran, G. Srinivas, Jayapal Gowardhane, et al.. Development and Validation of Stability Indicating RP-LC Method for Estimation of Ranolazine in Bulk and Its Pharmaceutical Formulations. American Journal of Analytical Chemistry. 2012;3:378-384.
- 23) Tapas Kumar Laha, Dibya Ranjan Padhy and Subrata Sen. A Validated Stability Indicating Reversed Phase High Performance Liquid Chromatographic Method Of Ranolazine Dihydrochloride And Characterization Of Its Degradation Products. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(1):61-66.
- 24) Suresh Babu VV, Sudhakar V, Murthy TEGK. Validated HPLC Method for Determining Related Substances in Compatibility Studies and Novel Extended Release Formulation for Ranolazine. J Chromatograph Separat Techniq. 2014;5(1):1-7.
- 25) A. Madhavi, D. V. Subba Rao, P. Srinivasu A. Naidu. Development and Validation of a New Analytical Method for the Determination of Related Components and Assay of Ranolazine in Bulk Drug and Pharmaceutical Dosage Forms by LC. Chromatographia. 2009;70:333-338.
- 26) Xingping Luo, Zongde Zhai, Xiaomei Wu, Yanping Shi, et. al. Analytical and semipreparative resolution of ranolazine enantiomers by liquid chromatography using polysaccharide chiral stationary phases. J. Sep. Sci. 2006;29:164-171.
- 27) Brahma Reddy Gade, B. Sitaram, hakavi, M. Satyanarayana, et al. Development and validation of stability indicating RP-LC method for estimation of ranolazine in bulk and its pharmaceutical formulations. Journal of Chemical and Pharmaceutical Research. 2015;7(8):454-461.
- 28) L. Xia, et al. Determination of Ranolazine in dog plasma by HPLC. West China Journal of Pharmaceutical Sciences;2010:4.
- 29) Lakshmi Priya. G, Haritha pavani. k, Nandakishore Agarwal, Development and Validation of stability indicating RP-HPLC method for estimation of ranolazine in bulk and Tablet Dosage form. International Research Journal of Pharmaceutical and Applied Sciences. 2012;2(5):217-223.
- 30) Saptarshi Ghosh, Ganesh Sawant, Banesh sooram, Jayeeta Bhaumik. In Silico Approach Towards Lipase Mediated Chemoenzymatic Synthesis of (S)-Ranolazine, as an Anti-Anginal Drug. RSC Adv. 2016;6: 49150-49157.
- 31) Vivek Nalawade, Parag Gide1, Govind Nunnaware1, Mitesh Phale. Development and validation of a LLE-HPLC method for the determination of Ranolazine in Human Plasma. International Journal of Pharmaceutical Sciences. 2010;2(1):369-374.
- 32) Malati, V, Reddy AR, Mukkanti K, Suryanarayana MV. A Novel reverse phase stability indicating RP-UPLC method for the quantitative determination of fifteen related substances in Ranolazine Drug Substance and Drug Product. Talanta. 2012;97:563-73.
- 33) Markus Jerling. Clinical pharmacokinetics of ranolazine. Clinical pharmacokinetics. 2006; 45(5):469-491
- 34) A.D. Penman, J. Eadie, W.J.herron, M.A. Reily, et al. The Characterization of the Metabolites of

- Ranolazine in Man by Liquid Chromatography Mass Spectrometry. *Rapid Communications in Mass Spectrometry*. 1995; 9:1418-1430.
- 35) XIE Lin, LIANG Yan, LIU Xiao Dong, Wang Guang Ji. Determination of Ranolazine and Its Pharmacokinetics in Dog by LC-MS. *Journal of China Pharmaceutical University*. 2004;2.
- 36) B. Shaobo, et al. Quantitative Determination of Ranolazine In Human Plasma By High Performance Liquid Chromatography-Tandem Mass Spectrometry. *Northwest Pharmaceutical Journal*. 2011;4.
- 37) Limei Zhao, Hao Li, Yao Jiang, Riyang Piao, et al. Determination of Ranolazine in Human Plasma by Liquid Chromatographic-Tandem Mass Spectrometric Assay. *Journal of Chromatographic Science*. 2008;46:697-700.
- 38) J. Zhong, et al. Determination of Ranolazine in Rat Plasma by Liquid Chromatography-Electrospray Ionization Mass Spectrometry. *Chromatographia*. 2006;63:123-127.
- 39) Lie Tian, Juanjuan Jiang, Yiling Huang, Lu Hua, et al., Sensitive Quantification Of Ranolazine In Human Plasma By Liquid Chromatography-Tandem mass spectrometry with positive electrospray ionization. *Journal of Chromatography B*. 2007;846: 346-50.
- 40) Uttam Bhaumik, Animesh Ghosh, Amlan Kanti Sarkar, Anirbandeep Bose, et al. Determination Of Ranolazine In Human Plasma by LC-MS/MS And Its Application In Bioequivalence Study. *Journal of Pharmaceutical and Biomedical Analysis*. 2008;48:1404-1410.
- 41) Yuan Wang, Xiaoyan Chen, Zuoming Sun, Yong Yang, et al. Development And Validation Of A Sensitive LC-MS/MS Assay For Simultaneous Quantitation Of Ranolazine and its three metabolites In Human Plasma. *Journal of Chromatography B*. 2012;889-890, 10-6.
- 42) Rodrigo Almeida Simoes, Thiago Barth, Pierina Sueli Bonato, Enantioselective analysis of Ranolazine And Desmethyl Ranolazine In Microsomal medium using dispersive liquid-Liquid Microextraction and LC-MS/MS. *Bioanalysis*. 2013;5(2):171-83.
- 43) Herron WJ, Eadie J, Penman AD. Estimation of Ranolazine and eleven phase I metabolites in human plasma by Liquid Chromatography-Atmospheric Pressure Chemical Ionisation Mass Spectrometry with Selected-Ion Monitoring. *Journal of Chromatography A*. 1995;712:55-60.
- 44) Yan Liang, Lin Xie, Xiao-Dong Liu, Wei-Dong Chen, et al. Simple, Sensitive and rapid Liquid Chromatography/ Atmospheric pressure chemical ionization Mass Spectrometric method for the quantitation of Ranolazine in Rat Plasma. *Rapid Communications in Mass Spectrometry*. 2006; 20:523-528.
- 45) Q. Tan, et al. Development And Validation Of A Sensitive U-HPLC-MS/MS method with Electrospray Ionization for quantitation of Ranolazine In Human Plasma: Application To A Clinical Pharmacokinetic Study. *Journal of Chromatography B*. 2012; 901:119-124.
- 46) B. Bhongade, et al. Diffuse Reflectance Infrared Fourier Transform Spectroscopy (DRIFTS) Application in Pharmaceutical Analysis: Method For Quantification Of Ranolazine in Tablet Dosage Form, *Vibrational Spectroscopy*, 2017;93: 52-56.
- 47) A. Khedkar, et al. Stability Indicating Method Development and Validation of Ranolazine Hydrochloride in Bulk and Tablet dosage form by HPTLC. *International Journal of Pharmaceutical and Clinical Research*. 2015;7(1):77-83.
- 48) Sreedhara Rao Abburu, Mohan Lakshmi Punna Rao Alapati, Anima S. Dadhich, Mutyala Krishnaji Rao, et al. Determination of Ranolazine in Tablet Formulations by High-Performance Thin-Layer Chromatography-Mass Spectrometry Using Reflectance Scanning Densitometry. *Journal of Planar Chromatography*. 2016;29(3):190-194.
- 49) O. Yahua, et al. Determination of Residual Organic Solvents in Ranolazine Dihydrochloride by Headspace Gas Chromatography. *China Pharmacist*. 2009:01.
- 50) Ya-Lin Ye, Xue-Mei Yang. Determination of Residual Solvents in Ranolazine By Headspace Gas Chromatography. *Journal of Southern Medical University*. 2008;28(1):134-135.